ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Recurrence"

  • 2017 American Transplant Congress

    A Pretransplant Model Incorporating Serum Biomarkers Is Superior to the Milan Criteria in Stratifying Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation: Analysis of 4407 Patients from the US Multicenter HCC Transplant Consortium.

    V. Agopian, On Behalf of the US Multicenter HCC Transplant Consortium.

    UCLA, LA

    Objective: While adoption of the Milan Criteria (MC) has improved outcomes following liver transplantation (LT) for hepatocellular carcinoma (HCC), recurrence remains a significant challenge. We…
  • 2017 American Transplant Congress

    Eculizumab Treatment on GC3 Recurrence on Renal Graft.

    G. Jeantet,1 D. Bertrand,3 A. Lionet,2 D. Anglicheau,4 V. Fremeaux-Bacchi,5 M. Le Quintrec.1

    1Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France; 2Department of Nephrology, Dialysis and Transplantation, Lille, France; 3Department of Nephrology, Dialysis and Renal Transplantation, Rouen, France; 4Transplantation Rénale, Necker Hospital, Paris, France; 5Immunology, Hopital Européen Georges Pompidou, Paris, France

    Clinical C3G recurrence occured in more than 50% after renal transplantation and is the first cause of allograft loss at 5 years post-transplantation. Eculizumab (EC)…
  • 2017 American Transplant Congress

    Is Peri-Transplant Plasmapheresis Effective in the Prevention of Recurrence of FSGS?

    P. Verghese, M. Rheault, S. Chinnakotla, S. Jackson, A. Matas, B. Chavers.

    University of Minnesota, Minneapolis

    Many pediatric centers utilize a variety of protocols including scheduled plasmapheresis to prevent the dreaded recurrence of focal segmental glomerulosclerosis (FSGS) post-transplant. But the effectiveness…
  • 2017 American Transplant Congress

    Renal Transplant Outcomes in Primary FSGS Compared with Other Recipients: A National Review of the Irish Transplant Registry.

    S. Cormican,1 C. Kennedy,1,2 P. O'Kelly,1 B. Doyle,3 A. Dorman,3 P. Conlon.1,2

    1Nephrology, Beaumont Hospital, Dublin, Ireland; 2Medicine, Royal College of Surgeons, Dublin, Ireland; 3Pathology, Beaumont Hospital, Dublin, Ireland

    Primary focal segmental glomerular sclerosis (p-FSGS) raises specific peri-transplant concerns, one of which is disease recurrence (r-FSGS). We aimed to compare transplant outcomes in patients…
  • 2017 American Transplant Congress

    Hepatitis B Virus Infection Is Associated with Recurrent Nephropathy After Kidney Transplantation.

    G. Chen, C. Wang, Z. Wu, C. Wang, J. Qiu, L. Chen.

    Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

    Background Hepatitis B virus(HBV) infection can cause HBV associated nephropathy, and is one of the major reasons for secondary nephropathy. We carried out a retrospective…
  • 2017 American Transplant Congress

    Long-Term Outcomes of Kidney Transplant Recipients with Primary Idiopathic Focal Segmental Glomerulosclerosis (FSGS).

    D. Khadzhynov, F. Halleck, L. Lehner, E. Schrezenmeier, K. Budde, O. Staeck.

    Nephrology, Charité Universitaetsmedizin, Berlin, Germany

    Introduction:Few data exists analyzing recurrence rates, treatment response and long-term outcomes in kidney transplant recipients (KTR) with primary FSGS.Methods: This retrospective observational study included 1218…
  • 2017 American Transplant Congress

    Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.

    M. Pereira,1 F. Silveira,2 G. Papanicolaou,3 A. Langston,4 R. Avery,5 A. Wijatyk,6 J. Wu,6 M. Boeckh,7 F. Marty,8 S. Villano.9

    1Columbia University Medical Center, New York, NY; 2University of Pittsburgh Medical Center, Pittsburgh, PA; 3Memorial Sloan Kettering Cancer Center, New York, NY; 4Winship Cancer Institute, Atlanta, GA; 5Johns Hopkins University, Baltimore, MD; 6Shire, Lexington, MA; 7Fred Hutchinson Cancer Research Center, Seattle, WA; 8Brigham and Women's Hospital, Boston, MA; 9Shire (At Time of Study), Wayne, PA

    Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…
  • 2017 American Transplant Congress

    Eculizumab Dose Reduction Is Safe by Monitoring Eculizumab Pre-Dose Level and Functional Complement Assays.

    M. Gelens,1 T. Havenith,2 J. Damoiseaux,3 M. Christiaans.1

    1Internal Medicine, MUMC, Maastricht, Netherlands; 2Clinical Pharmacy, MUMC, Maastricht, Netherlands; 3Central Diagnostic Laboratory, MUMC, Maastricht, Netherlands

    Background & aims: Untreated atypical haemolytic syndrome (aHUS) leads to ESRD and may recur after renal transplantation. Eculizumab (Ecu), a humanized antibody inhibiting terminal C5…
  • 2017 American Transplant Congress

    Prognostic Significance of Preoperative Neutrophil-Lymphocyte Ratio in Patients Undergoing Liver Transplantation with Hepatocellular Carcinoma within Milan Criteria.

    S.-K. Kwon,1 J. Lee,1 S. Song,1 J. Lee,1 D. Kim,1 J. Lee,2 M. Kim,1 G. Choi,1 J. Choi,1 D. Han,1 S. Kim,1 D. Joo.1

    1Department of Surgery, Yonsei University College of Medicine, Seoul, Korea; 2Department of Surgery, CHA University, Bundang, Korea

    Introduction: The systemic inflammation biomarker, neutrophil-to-lymphocyte ratio (NLR) has been reported to be a predioctor of poor survival in patients with various cancers. The purpose…
  • 2017 American Transplant Congress

    Novel Insights into the Synergism of CD40 Autoantibodies and suPAR in Kidney Transplant Patients with FSGS Recurrence.

    T. Sigdel, C. Wei, F. Vencenti, J. Reiser, M. Sarwal.

    University of California San Francisco, San Francisco

    Background: FSGS is a histopathological lesion that has a 40-80% risk of recurrence o in the transplanted (tx) kidney, with increased risk of graft loss.…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 15
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences